SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Caution urged in Europe over summer easing
Fri June 11th - The World Health Organisation has urged caution as European countries seek to ease pandemic restrictions over the summer. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

India trial finds limited effectiveness from convalescent plasma

Friday October 23rd 2020

Using convalescent plasma to treat moderately ill COVID-19 patients did not reduce severity of the illness or risk of death, according to the findings of a small clinical trial published today.

The Indian study involved 464 patients while a major UK study, whose leaders remain optimistic, currently has more than 1,700 patients and aims to be the largest in the world.

The trial, led by researchers at the Indian Council of Clinical Research, in New Delhi, India, found that while convalescent plasma appeared to improve shortness of breath and fatigue, and led to higher negative conversion after seven days, it did not translate into a reduction in deaths or progression to severe disease by 28 days.

They investigated the effectiveness of convalescent plasma after some countries, including the USA and India, authorised it for emergency use, while others, such as the UK, are collecting donated plasma so that it can be rolled out if shown to be effective.

The study, published in the latest edition of The BMJ, involved 464 adults, whose average age was 52 and who were admitted to 39 public and private hospitals across India between 22 April and 14 July 2020. All had confirmed moderate COVID-19.

The patients were randomly split into two groups, with the 235-strong intervention group receiving two transfusions of convalescent plasma, 24 hours apart, alongside best standard of care, while the control group of 229 patients received best standard of care only.

The plasma samples were checked for safety and the levels of neutralising antibodies were also measured. All participants underwent clinical examination and a range of laboratory tests at the start of the trial and again on days one, three, five, seven and 14, and were contacted by telephone on day 28.

After 28 days, 44 (19%) participants in the intervention group and 41 (18%) in the control group had developed severe disease or had died from any cause.

The researchers say the study design ensured that the only important difference between the two groups of patients was whether they received convalescent plasma. Restricting the comparison to patients who received plasma with detectable antibody levels did not change the results.

Although they acknowledge some limitations, such as differences in the number of patients, laboratory tests, and standards of care across the trial sites that may have affected their results, they say the wide social, cultural, and economic mix of study participants mean the findings are likely to apply more generally.

They conclude that because it showed limited effectiveness, future research could explore using only plasma with high levels of neutralising antibodies, to see if this might be more effective.

* In the UK researchers have increased collection of convalescent plasma, opening 14 additional collection centres and increasing the number by half.

NHS Blood and Transplant has already collected 9,000 units of plasma for the project.

Its associate medical director Professor David Roberts said: “We have so far seen a fantastic response from the public coming forward to donate plasma. We are rapidly building our capability to collect plasma so that we can move into supplying hospitals at scale, should the trial demonstrate patient benefit.”

A UK government minister Lord Bethell said: “The use of convalescent plasma has shown promising results in treating coronavirus and the opening of more donation centres is an important step towards getting this innovative treatment to more patients, if clinical trials demonstrate it should be available on the NHS.”

Agarwal A, Mukherjee A, Kumar G et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 23 October 2020

https://www.bmj.com/content/371/bmj.m3939

Tags: Asia | Flu & Viruses | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES